SNGX News and Press, Soligenix Inc. From 07/22/21

Soligenix Demonstrates Clinical Success in First-in-Class Treatment for Cutaneous T-Cell Lymphoma   New York, NY - ( NewMediaWire ) - July 22, 2021 - PCG Digital -- Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin’s lymphoma that currently affects between...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you think Reddit is only a social media network, you’ve missed one of its most popular applications over the past year: a forum for stock traders. Retail investors famously used the platform to drive short squee...

Gainers: Virpax Pharmaceuticals (VRPX) +46%. Opiant Pharmaceuticals (OPNT) +31%. OncoSec Medical (ONCS) +24%. Dare Bioscience (DARE) +18%. Biohaven Pharmaceutical Holding Company (BHVN) +12%.Losers: IDEAYA Biosciences (IDYA) -24%. Cleveland BioLabs (CBLI) -20%. Soligenix (SNGX) -16%...

BSQUARE (BSQR) -21% on Q2 prelim financial resultsBridgeline Digital (BLIN) -16%.Marin Software (MRIN) -10%.Red Cat Holdings (RCAT) -9%.Soligenix (SNGX) -9% Conversation with Dr. Ellen Kim on HyBryte™data and the current treatment landscape for CTCL.Staffing 360 Solutions (ST...

New York, NY, July 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- PCG Digital -- A rare form of non-Hodgkin’s lymphoma, cutaneous T-cell lymphoma (CTCL) has no current FDA-approved first-line therapies. There are roughly 3,000 new CTCL cases in the United States each y...

NEW YORK, NY - ( NewMediaWire ) - July 06, 2021 - PCG Digital -- A rare form of non-Hodgkin’s lymphoma, cutaneous T-cell lymphoma (CTCL) has no current FDA-approved first-line therapies. There are roughly 3,000 new CTCL cases in the United States each year, with more than 20,000 patie...

RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the thr...

Soligenix (SNGX) announces key details of HyBryte (hypericin ointment 0.25%) in the the Phase 3 FLASH study in cutaneous T-cell lymphoma ((CTCL)) at the USCLC Annual Meeting, to be held on June 26, 2021. The Phase 3 FLASH trial enrolled a total of 169 patients (166 evaluable). The t...

HyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting Key efficacy and safety data from the study in CTCL to be highlighted PR Newswire PRINCETON, N.J. , June 22,...

Soligenix (SNGX) jumps 13% premarket after receiving a Pediatric Investigation Plan ((PIP)) waiver from the EMA for HyBryte (SGX301 or hypericin), which has recently and successfully concluded a Phase 3 study for the treatment of early stage cutaneous T-cell lymphoma ((CTCL)). ...